Newsletter Signup | Join Community
Impotence, a common complication of prostate surgery may be reversible with minimally invasive end to end nerve grafting
Become an empowered partner by learning about this common cancer type.
Men with prostate cancer have genomic defects that can be targeted with Lynparza and should undergo genomic testing.
Xtandi® + Zytiga® does not improve survival in advanced prostate cancer compared to Xtandi alone.
Erleada prolongs survival in non-metastatic Castration-resistant Prostate Cancer and for those with metastatic disease.
Initial results of KEYNOTE 365 study of Keytruda immunotherapy in prostate cancer released at 2019 ASCO
Xtandi® superior to non-steroidal anti-androgens and improves survival in all phases of advanced prostate cancer.
Urologists are one of the experts that treat prostate cancer with surgery or prostatectomy. How do you choose one?
Oncotype DX - Prostate The Beginning of Individualized Treatment
Studies demonstrate that Zytiga improves outcomes in men with newly diagnosed and ADT resistant prostate cancer.
Harvard Study on Statins lowering risk of prostate cancer. …
Tell Your PSA Story: Has the PSA test helped in your prostate cancer journey? Its Prostate Cancer…